HDAC6 and amyotrophic lateral sclerosis: In a therapeutic approach targeting the histone deacetylase 6 (HDAC6) using antisense oligonucleotides or with pharmacological inhibitors (Tubastatin A and ACY-738), we demonstrated the successful rescue of MAM integrity and PC levels in MNs derived from FUS-ALS patient iPSCs [196].